ASH 2019 – Orlando. The big “late-breaking” news at the American Society of Hematology Annual Meeting are the results of the phase III Candor trial. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) in this video the main results of this clinical trial. Continue reading
Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) summarised for Myeloma Patients Europe (MPE) the main updates on AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting held from 7 to 10 December 2019 in Orlando, Florida, USA. Continue reading
ASH 2019, Orlando – Even though autologous hematopoietic cell transplantation (AHCT), a form of stem cell therapy, is an effective treatment for multiple myeloma, only four out of 10 patients receive this therapy. Myeloma occurs most often in people over 60 and the age is usually the main reason for avoiding this procedure. Continue reading
ASH 2019, Orlando – Belantamab mafodotin is a new myeloma drug that has shown very promising results. The clinical trial Dreamm-3 was presented yesterday at the American Society of Hematology (ASH) Annaul Congress and it is expected to be the European approval trial for this drug.
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) what we need to know about this first-in-class drug. Continue reading
ASH 2019, Orlando – A number of early-phase studies were presented yesterday during the 61st American Society of Hematology (ASH) Annual Meeting spotlight the rapid advances being made in cellular immunotherapy for blood cancers. Researchers will present the results of early-phase studies of emerging “second-generation” cellular immunotherapy products that strive to overcome the limitations of existing products. Continue reading
ASH 2019, Orlando – More than 25.000 attendees from more than 115 countries gather together in the 61st American Society of Hematology (ASH) Annual Congress. This is the largest world congress of hematology and will be held from today to 10 December 2019 in Orlando, Florida, USA. Continue reading
ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a press release publish by the Harmony Alliance. Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance. Continue reading
MPE staff members
MPE is looking for a Senior Office Assistant. Would you like to join the MPE team? Apply for this job offer by sending your CV and motivation letter to Ananda Plate plate@mpeurope.org.
- Full time / permanent
- Approx. 10 days of travel per year
- Munich, Germany
- Salary: 35.000-40.000 EUR GROSS per year
More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA. Continue reading
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019. Continue reading